公开(公告)号：EP2841086B1

公开(公告)日：2018-09-26

申请号：EP13775928.8

申请日：2013-04-09

Applicant: Case Western Reserve University

Inventor： LANG, Bradley, T. ,  CREGG, Jared M. ,  SILVER, Jerry ,  WANG, Yi-Lan

IPC: A61K38/17 ,  A61K38/16 ,  A61P35/00 ,  A61K38/46

CPC classification number: A61K38/465 ,  C12Y301/03048

Abstract: A method of inhibiting and/or reducing the activity, signaling, and/or function of leukocyte-common antigen related (LAR) family of phosphatases in a cell of a subject induced by proteoglycans includes administering to the cell a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases without inhibiting binding to or activation the LAR family phosphatases by the proteoglycans.

公开(公告)号：EP0493533A1

公开(公告)日：1992-07-08

申请号：EP90917627.0

申请日：1990-10-26

Applicant: Case Western Reserve University ,  GLIATECH, INC.

Inventor： SNOW, Diane, M. ,  SILVER, Jerry ,  HAREL, Adrian ,  ROUFA, Dikla

IPC: A61K31 ,  C07K16 ,  C12N9

CPC classification number: A61K31/715 ,  A61K31/70 ,  C07K16/18 ,  C12N9/2408 ,  Y02A50/472 ,  A61K2300/00

Abstract: The present invention is directed to methods of using keratan sulfate, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, and hyaluronic acid, and molecules and compositions comprising keratan sulfate, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, and hyaluronic acid, to inhibit or prevent neurite outgrowth, i.e., axonal growth, or nerve regeneration (colectively termed herein ''nerve growth''), or glial cell migration or invasion, or regeneration, and therapeutically, where the foregoing is desired. In another embodiment of the invention, inhibitors and antagonists of keratan sulfate, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, and hyaluronic acid, and molecules and compositions containing the same, may be used to promote nerve growth or glial cell migration or invasion, and can be administered therapeutically. Such inhibitors and antagonists include but are not limited to antibodies, degradative enzymes, lectins; and disaccharide antagonists of the receptors for keratan sulfate, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin or hyaluronate.